KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Cash from Investing Activities: 2019-2024

Historic Cash from Investing Activities for AbCellera Biologics (ABCL) over the last 6 years, with Dec 2024 value amounting to $121.4 million.

  • AbCellera Biologics' Cash from Investing Activities rose 886.70% to $36.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.3 million, marking a year-over-year decrease of 21.29%. This contributed to the annual value of $121.4 million for FY2024, which is 154.91% up from last year.
  • According to the latest figures from FY2024, AbCellera Biologics' Cash from Investing Activities is $121.4 million, which was up 154.91% from -$221.1 million recorded in FY2023.
  • AbCellera Biologics' Cash from Investing Activities' 5-year high stood at $121.4 million during FY2024, with a 5-year trough of -$352.6 million in FY2022.
  • Its 3-year average for Cash from Investing Activities is -$150.8 million, with a median of -$221.1 million in 2023.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first slumped by 1,972.32% in 2020, then skyrocketed by 154.91% in 2024.
  • AbCellera Biologics' Cash from Investing Activities (Yearly) stood at -$119.8 million in 2020, then plummeted by 177.38% to -$332.2 million in 2021, then decreased by 6.13% to -$352.6 million in 2022, then spiked by 37.30% to -$221.1 million in 2023, then spiked by 154.91% to $121.4 million in 2024.